NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE GUIDANCE

The Management of Atrial Fibrillation

http://www.nice.org.uk/guidance/CG180

Atrial Fibrillation Quality Standard

www.nice.org.uk/guidance/qs93

Venous thromboembolism: reducing the risk: Reducing the risk of venous thromboembolism (deep vein thrombosis and pulmonary embolism) in patients admitted to hospital

http://www.nice.org.uk/guidance/CG92

Venous thromboembolic diseases: the management of venous thromboembolic diseases and the role of thrombophilia testing

http://www.nice.org.uk/guidance/CG144

Quality Standard for diagnosis and management of thromboembolic diseases

http://www.nice.org.uk/quality/QS29

NICE Pathways – Mapping the guidance

This online tool provides quick and easy access, topic by topic, to the range of guidance from NICE, including quality standards, technology appraisals, clinical, public health and social care guidelines and NICE implementation tools.

http://pathways.nice.org.uk/
Atrial fibrillation and heart valve disease: self monitoring coagulation status using point-of-care coagulometers (the CoaguChek XS system and the INRatio2 PT/INR monitor)

http://www.nice.org.uk/guidance/dg14

Guidance for anticoagulants

Apixaban

Apixaban for the prevention of venous thromboembolism after total hip or knee replacement in adults
http://www.nice.org.uk/guidance/TA245

Apixaban for preventing stroke and systemic embolism in people with nonvalvular atrial fibrillation
http://www.nice.org.uk/guidance/TA275

Apixaban for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism
http://www.nice.org.uk/guidance/TA341

Dabigatran

Dabigatran Etexilate for the prevention of venous thromboembolism after hip or knee replacement surgery in adults
http://www.nice.org.uk/guidance/TA157

Dabigatran Etexilate for preventing stroke and systemic embolism in people with nonvalvular atrial fibrillation
http://www.nice.org.uk/guidance/TA249

Dabigatran Etexilate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism
http://www.nice.org.uk/guidance/TA327

Dabigatran Etexilate Reversal Agent  Idarucizumab
https://www.nice.org.uk/advice/esnm73/chapter/Key-points-from-the-evidence

https://www.scottishmedicines.org.uk/SMC_Advice/Advice/1178_16_idarucizumab_Praxbind/idarucizumab_Praxbind
Edoxaban

Edoxaban for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation

http://www.nice.org.uk/guidance/TA355

Edoxaban for treating and preventing deep vein thrombosis and pulmonary embolism

http://www.nice.org.uk/guidance/TA354

Rivaroxaban

Rivaroxaban for the prevention of venous thromboembolism after hip or knee replacement surgery in adults

http://www.nice.org.uk/guidance/TA170

Rivaroxaban for preventing stroke and systemic embolism in people with nonvalvular atrial fibrillation

http://www.nice.org.uk/guidance/TA256

Rivaroxaban for treating deep vein thrombosis and preventing recurrent deep vein thrombosis and pulmonary embolism after a diagnosis of acute deep vein thrombosis in adults

http://www.nice.org.uk/guidance/TA261

Rivaroxaban treatment of acute symptomatic pulmonary embolism with or with or without symptomatic deep vein thrombosis and the prevention of recurrent VTE events

http://www.nice.org.uk/guidance/TA561

Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome

http://www.nice.org.uk/guidance/TA335

SCOTTISH MEDICINES CONSORTIUM ADVICE

SMC advice relating to Apixaban, Dabigatran, Edoxaban and Rivaroxaban and their indications can be found in the SMC Advice Directory

http://www.scottishmedicines.org.uk/Home

OTHER GUIDELINES - DEVICES
**The geko device for reducing the risk of venous thromboembolism**

The Geko device looks like a small wristwatch that is attached below the knee. It stimulates the muscles in the leg and foot and may help to reduce the risk of blood clots forming. NICE has said that the Geko can be used for people in whom it is not possible to use other methods of preventing blood clots.

NICE medical technology guidance (MTG19) Published June 2014

Anticoagulation UK, PO Box 405, Bromley, BR2 9WP
Email: info@anticoagulationuk.org